RE:Buyout numbersI've already provided my take, particularly since ONCY has targeted the metastatic pancreatic, breast, and colorectal cancer markets with a biomarker driven biological in the form of pelareorep, which is eligible for 13 years of FDA market exclusivity on each indication approved. And the markets for these cancers are significant as already stated.